Tumours of these patients almost universally lose both functional copies of the BRCA1 or BRCA2 gene, either by loss of heterozygosity (LOH) of the wild-type allele or, more rarely, by the acquisition of a somatic mutation in the wild-type locus [6]. The gene discussed is BRCA2; the disease is neoplasm.